vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Huntsman CORP (HUN). Click either name above to swap in a different company.

Huntsman CORP is the larger business by last-quarter revenue ($1.4B vs $749.2M, roughly 1.8× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — 3.6% vs -7.1%, a 10.7% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -6.7%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -4.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Huntsman Corporation is an American multinational manufacturer and marketer of chemical products for consumers and industrial customers. Huntsman manufactures assorted polyurethanes, performance products, and adhesives for customers like BMW, GE, Chevron, Procter & Gamble, Unilever and Walkaroo. With global headquarters in The Woodlands, Texas, it operates more than 60 manufacturing, R&D and operations facilities in over 25 countries and employ approximately 7,000 associates across three busi...

CLOV vs HUN — Head-to-Head

Bigger by revenue
HUN
HUN
1.8× larger
HUN
$1.4B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+68.7% gap
CLOV
62.0%
-6.7%
HUN
Higher net margin
CLOV
CLOV
10.7% more per $
CLOV
3.6%
-7.1%
HUN
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-4.0%
HUN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
HUN
HUN
Revenue
$749.2M
$1.4B
Net Profit
$27.3M
$-96.0M
Gross Margin
12.1%
Operating Margin
3.6%
-4.4%
Net Margin
3.6%
-7.1%
Revenue YoY
62.0%
-6.7%
Net Profit YoY
31.9%
EPS (diluted)
$0.05
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
HUN
HUN
Q1 26
$749.2M
Q4 25
$487.7M
$1.4B
Q3 25
$496.6M
$1.5B
Q2 25
$477.6M
$1.5B
Q1 25
$462.3M
$1.4B
Q4 24
$337.0M
$1.5B
Q3 24
$331.0M
$1.5B
Q2 24
$356.3M
$1.6B
Net Profit
CLOV
CLOV
HUN
HUN
Q1 26
$27.3M
Q4 25
$-49.3M
$-96.0M
Q3 25
$-24.4M
$-25.0M
Q2 25
$-10.6M
$-158.0M
Q1 25
$-1.3M
$-5.0M
Q4 24
$-22.1M
$-141.0M
Q3 24
$-9.2M
$-33.0M
Q2 24
$7.4M
$22.0M
Gross Margin
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
12.1%
Q3 25
14.0%
Q2 25
12.5%
Q1 25
14.3%
Q4 24
12.9%
Q3 24
24.5%
15.2%
Q2 24
30.3%
15.4%
Operating Margin
CLOV
CLOV
HUN
HUN
Q1 26
3.6%
Q4 25
-10.1%
-4.4%
Q3 25
-4.9%
0.4%
Q2 25
-2.2%
-8.2%
Q1 25
-0.3%
3.0%
Q4 24
-6.4%
-4.3%
Q3 24
-2.7%
2.7%
Q2 24
2.0%
2.2%
Net Margin
CLOV
CLOV
HUN
HUN
Q1 26
3.6%
Q4 25
-10.1%
-7.1%
Q3 25
-4.9%
-1.7%
Q2 25
-2.2%
-10.8%
Q1 25
-0.3%
-0.4%
Q4 24
-6.6%
-9.7%
Q3 24
-2.8%
-2.1%
Q2 24
2.1%
1.4%
EPS (diluted)
CLOV
CLOV
HUN
HUN
Q1 26
$0.05
Q4 25
$-0.56
Q3 25
$-0.14
Q2 25
$-0.92
Q1 25
$-0.03
Q4 24
$-0.82
Q3 24
$-0.19
Q2 24
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
HUN
HUN
Cash + ST InvestmentsLiquidity on hand
$177.6M
$429.0M
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$339.4M
$2.8B
Total Assets
$697.7M
$7.0B
Debt / EquityLower = less leverage
0.73×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
HUN
HUN
Q1 26
$177.6M
Q4 25
$78.3M
$429.0M
Q3 25
$468.0M
Q2 25
$399.0M
Q1 25
$334.0M
Q4 24
$194.5M
$340.0M
Q3 24
$288.0M
$330.0M
Q2 24
$254.8M
$335.0M
Total Debt
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
$2.0B
Q3 25
$2.0B
Q2 25
$2.0B
Q1 25
$2.0B
Q4 24
$1.8B
Q3 24
$1.9B
Q2 24
$1.9B
Stockholders' Equity
CLOV
CLOV
HUN
HUN
Q1 26
$339.4M
Q4 25
$308.7M
$2.8B
Q3 25
$340.9M
$2.8B
Q2 25
$344.2M
$2.8B
Q1 25
$336.1M
$3.0B
Q4 24
$341.1M
$3.0B
Q3 24
$342.2M
$3.1B
Q2 24
$324.9M
$3.1B
Total Assets
CLOV
CLOV
HUN
HUN
Q1 26
$697.7M
Q4 25
$541.0M
$7.0B
Q3 25
$559.7M
$7.1B
Q2 25
$575.0M
$7.1B
Q1 25
$583.7M
$7.2B
Q4 24
$580.7M
$7.1B
Q3 24
$653.0M
$7.3B
Q2 24
$674.2M
$7.3B
Debt / Equity
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
0.73×
Q3 25
0.73×
Q2 25
0.72×
Q1 25
0.66×
Q4 24
0.62×
Q3 24
0.60×
Q2 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
HUN
HUN
Operating Cash FlowLast quarter
$76.0M
Free Cash FlowOCF − Capex
$19.0M
FCF MarginFCF / Revenue
1.4%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$116.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
$-66.9M
$76.0M
Q3 25
$12.1M
$196.0M
Q2 25
$5.4M
$91.0M
Q1 25
$-16.3M
$-74.0M
Q4 24
$34.8M
$153.0M
Q3 24
$50.0M
$129.0M
Q2 24
$44.8M
$46.0M
Free Cash Flow
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
$-69.0M
$19.0M
Q3 25
$11.4M
$153.0M
Q2 25
$4.8M
$54.0M
Q1 25
$-16.5M
$-110.0M
Q4 24
$33.3M
$102.0M
Q3 24
$49.6M
$88.0M
Q2 24
$44.4M
$-4.0M
FCF Margin
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
-14.1%
1.4%
Q3 25
2.3%
10.5%
Q2 25
1.0%
3.7%
Q1 25
-3.6%
-7.8%
Q4 24
9.9%
7.0%
Q3 24
15.0%
5.7%
Q2 24
12.5%
-0.3%
Capex Intensity
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
0.4%
4.2%
Q3 25
0.1%
2.9%
Q2 25
0.1%
2.5%
Q1 25
0.0%
2.6%
Q4 24
0.5%
3.5%
Q3 24
0.1%
2.7%
Q2 24
0.1%
3.2%
Cash Conversion
CLOV
CLOV
HUN
HUN
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

HUN
HUN

Diversified$897.0M66%
Specialty$231.0M17%
Performance Products$113.0M8%
Advanced Materials$61.0M5%
Related Party Customers$19.0M1%
Other$12.0M1%

Related Comparisons